Compliance & Medical Disclaimer
This article is for informational and educational purposes only and does not constitute medical, legal, regulatory, or professional advice. The compounds discussed are research chemicals not approved for human consumption by the US FDA, European Medicines Agency (EMA), UK MHRA, Australian TGA, Health Canada, or any other major regulatory authority. They are sold strictly for laboratory research use. WolveStack does not employ medical staff, does not diagnose, treat, or prescribe, and makes no health claims under FTC, UK ASA, EU MDR/UCPD, or AU TGA standards. Always consult a licensed healthcare professional in your jurisdiction before considering any peptide protocol. This site contains affiliate links (FTC 2023 endorsement guidelines compliant); we may earn a commission on qualifying purchases at no additional cost to you. Some compounds discussed are on the WADA prohibited list — competitive athletes should verify current status with their governing body before any research use. Use of research chemicals may be illegal in your jurisdiction.
IMPORTANT: This compound is currently on the World Anti-Doping Agency (WADA) prohibited list. Competitive athletes face sanctions for use including in retirement testing programs. Verify current WADA status with your sport's governing body before any research involvement.
Editorial policy
Editorial review process: WolveStack Research Team — collective expertise in peptide pharmacology, regulatory science, and research literature analysis. We synthesize peer-reviewed studies, regulatory filings, and clinical trial data; we do not provide medical advice or treatment recommendations. Content is reviewed and updated as new evidence emerges.
Medical Disclaimer
For informational and educational purposes only. Not FDA-approved for human use. Consult a licensed healthcare professional. See full disclaimer.
CJC-1295 DAC is a growth hormone-releasing hormone (GHRH) analog that stimulates natural GH production via pituitary signaling. The DAC (Drug Affinity Complex) modification extends half-life to 6-8 days, requiring only 1-2 weekly injections. Beginners should start with 1 mg weekly for 12 weeks, expect sleep quality improvements within weeks 1-2 and visible body composition changes by weeks 4-8.
What Exactly Is CJC-1295 DAC?
CJC-1295 DAC is a synthetic peptide consisting of 30 amino acids designed to mimic human GHRH (growth hormone-releasing hormone). It functions by binding GHRH receptors on pituitary somatotroph cells, triggering increased growth hormone synthesis and secretion. Unlike exogenous HGH replacement therapy (which provides synthetic hormone directly), CJC-1295 works WITH your body's endogenous GH production system, stimulating your pituitary gland to produce more of its own hormone. The DAC modification (polyethylene glycol-albumin complex attached to the peptide backbone) extends the peptide's circulatory lifespan from 30 minutes (non-DAC version) to 6-8 days, enabling once or twice-weekly injection rather than daily. This extended half-life creates continuous GHRH signaling, producing sustained GH elevation rather than episodic pulses.
Why Choose CJC-1295 DAC Instead of Other Options?
Three primary alternatives exist: (1) Non-DAC CJC-1295: requires 1-3 daily injections (inconvenient, lower compliance), (2) Exogenous HGH: requires medical prescription, expensive, suppresses endogenous GH production, (3) Other peptides: Ipamorelin, GHRP variants (distinct mechanisms, often stacked with CJC). DAC advantages: convenient (1-2 weekly injections), maintains endogenous GH production system (unlike exogenous HGH), evidence-based dosing from ConjuChem clinical trials, excellent safety profile, cost-effective compared to prescription HGH. DAC disadvantages: sustained (non-physiologic) GH profile rather than natural pulsatile, slightly higher desensitization risk than non-DAC. For beginners prioritizing convenience and compliance, DAC is superior; for beginners prioritizing physiologic pulsatility, non-DAC is better despite daily injections.
First-Cycle Protocol: Conservative but Effective
Beginner protocol: 1 mg CJC-1295 DAC, once weekly (Monday morning or evening), subcutaneous injection into abdomen/thigh/deltoid, for 12 weeks straight, followed by 6-week complete break. This conservative dosing (1 mg weekly) aligns with clinical trial evidence and permits subjective response assessment without overwhelming side effects. Expected results: improved sleep quality weeks 1-2 (most noticeable early benefit), improved energy/mood weeks 2-4, visible body composition changes (fat loss + muscle definition) weeks 4-8, maximum benefits weeks 8-12. Blood work: optional IGF-1 testing at week 6 (confirms drug absorption and GH elevation); many beginners skip labs and rely on subjective benefits.
How to Administer: Step-by-Step Injection Guide
Setup: CJC-1295 DAC arrives as lyophilized powder (typically 2 mg vial). Reconstitution: use 1-2 mL bacteriostatic water (provided separately) injected into vial. Shake gently until fully dissolved (clear solution). Draw 1 mL reconstituted solution (1 mg dose) into insulin syringe (31-gauge, 0.5 inch needle). Injection: pinch skin on abdomen/thigh/deltoid, inject subcutaneously at 45-degree angle, inject entire 1 mL, withdraw needle. Pressure: apply slight pressure with cotton swab for 10 seconds. Timing: Monday morning or Monday evening (consistent day weekly optimizes compliance). Storage: refrigerate reconstituted solution (2-8°C) for up to 4 weeks. First injection anxiety is normal—most research subjects report negligible injection pain within 3-4 practice injections.
What to Expect Week-by-Week
Weeks 1-2: Sleep quality improvements (deeper sleep, faster sleep onset, fewer awakenings). Energy elevation beginning. Mood improvement (increased motivation). Weeks 3-4: Subjective energy/recovery improvements. IGF-1 accumulation reaching 50% of peak. Weeks 4-6: Visible body composition changes emerging (slight waist circumference reduction, muscle definition increasing). Appetite increase (beneficial for bulking, requires caloric discipline if cutting). Weeks 6-8: Measurable fat loss (2-5 lbs typically) and visible muscle gain. Recovery improved (fewer training off-days needed). Weeks 8-12: Maximum transformation period. Fat loss accelerates, muscle definition improves dramatically, skin quality improves noticeably. Sleep remains elevated. Weeks 13-16 (optional extension): benefits plateau, desensitization beginning, diminishing returns. Most beginners stop at week 12 and begin 6-week break.
Common Beginner Mistakes and How to Avoid Them
(1) Inadequate fasting before injection: injecting post-meal reduces GH response 50-70%. Solution: inject on empty stomach (minimum 4 hours post-meal). (2) Inconsistent injection timing: missing weekly injection or varying injection days. Solution: set phone reminder for same day every week (Monday automatically). (3) Excessive expectations: expecting overnight results. Solution: understand results timeline (weeks 4-8 for visible changes, 12 weeks for full cycle benefits). (4) Poor nutrition/training: expecting CJC alone to create results without training stimulus. Solution: maintain or increase training intensity during cycle. (5) Insufficient off-cycle: restarting cycle before receptor recovery (4+ week break minimum). Solution: enforce mandatory 6-week break between cycles to allow full recovery. (6) Neglecting sleep: GH effects amplified by quality sleep; poor sleep dampens results. Solution: prioritize 7-9 hours consistent nightly sleep during cycle. (7) Dehydration: GH causes water retention, which requires adequate daily hydration. Solution: consume minimum 3-4 liters water daily.
Trusted Research-Grade Sources
Below are the two vendors we recommend for research peptides — both publish independent third-party Certificates of Analysis (COAs) and ship internationally. Affiliate links: we earn a small commission at no extra cost to you (see Affiliate Disclosure).
Particle Peptides
Independently HPLC-tested, transparent COAs, comprehensive product range.
Browse Particle Peptides →Limitless Life Nootropics
Premium research peptides with strong customer support and verified purity.
Browse Limitless Life →Frequently Asked Questions for Beginners
How do I know if CJC-1295 DAC is working?
Early signs: improved sleep (weeks 1-2), increased energy (weeks 2-4), visible body composition changes (weeks 4-8). Objective confirmation: IGF-1 blood work at week 6 should show 100-150% elevation above baseline. Subjective improvements + IGF-1 elevation confirms legitimate drug effect.
What if I don't see results by week 8?
Troubleshoot: confirm proper fasting (inject empty stomach), verify consistent injection timing (same day weekly), assess training stimulus (inadequate training prevents results realization), check nutrition (insufficient protein/calories prevent lean mass gain). Hypo-responders (genetically low GH sensitivity) may require dose escalation to 1.5-2 mg weekly after week 4-6 assessment.
Can I start CJC-1295 DAC without medical supervision?
Technically yes; ConjuChem trials documented safety without ongoing medical monitoring. However, baseline health screening (blood work, cancer screening if age 40+) before initiation is prudent. Many beginners arrange single medical consultation pre-cycle for baseline labs, then self-monitor.
Do I need to follow a specific diet while using CJC-1295 DAC?
No mandatory diet; results optimize with adequate protein (0.8-1 g per lb bodyweight) and training stimulus. Bulking diets (caloric surplus) maximize muscle gain; cutting diets (deficit) maximize fat loss. CJC amplifies training response regardless of diet, but diet modifies body composition direction.
What happens if I miss an injection?
Single missed weekly injection produces minimal effect due to 6-8 day half-life (previous injection still circulating). Resume normal schedule next week (don't double-dose). Systematic missed injections (>30% of protocol) reduce effectiveness proportionally.
Can I increase dosage during my first cycle if results are slow?
Wait minimum 4-6 weeks before escalating dose (allows accurate response assessment after 3-4 half-lives). If week 6 IGF-1 shows inadequate elevation (<50% above baseline) OR week 8 shows minimal visible changes, increase to 1.5 mg weekly for weeks 7-12. Don't guess; let blood work guide escalation decisions.
Building a Post-Cycle Recovery Plan: Protecting Your Gains
A 12-week CJC-1295 DAC cycle is just the beginning—what you do in the 4-8 weeks after defines whether gains stick around or fade. The pituitary needs recovery time to restore endogenous GH secretion (suppressed during the cycle). This doesn't mean cessation is dangerous, but strategic post-cycle support maximizes durability. Continue resistance training at 100% intensity throughout the break; muscle protein synthesis remains elevated for 2-3 weeks post-cycle, and training stimulus locks in gains. Protein intake (1g per lb bodyweight) remains high. Sleep (7-9 hours) is critical because endogenous GH recovery happens during deep sleep—sleep deprivation delays pituitary recovery by 1-2 weeks.
Supplement support during the break can accelerate GH axis recovery. Amino acids L-arginine (3-5 g before bed) and L-ornithine (2-3 g before bed) stimulate endogenous GH release modestly; they're not replacements for CJC-1295 DAC but support the pituitary during recovery. Zinc (30-50 mg daily) is essential for endogenous GH and IGF-1 production—many bodybuilders become zinc-depleted during intense training, impairing recovery. Magnesium glycinate (300-500 mg before bed) supports sleep quality and GH-promoting deep sleep architecture. These are low-cost, evidence-supported additions to a post-cycle protocol.
By week 8 post-cycle, endogenous GH typically recovers to 80-90% of pre-cycle baseline levels (full recovery takes 12-16 weeks, but most functional recovery happens by week 8). At this point, you can assess whether a second cycle is warranted. For beginners, spacing cycles 8-12 weeks apart (total on/off cycle length = 20-24 weeks) allows brain axis recovery while capturing multi-cycle benefits. More aggressive users run 6-week breaks between cycles (12-week on, 6-week off, repeat), maintaining chronically elevated IGF-1 and accelerating annual progress, but this approach carries higher desensitization risk and requires medical monitoring.